ALKBH5 and breast carcinoma: Combining previous studies with the in vitro and in vivo results from this research, we hypothesize that NGR-labeled ALKBH5 siRNA may inhibit ITGB1 expression by promoting the m6A-dependent degradation of ITGB1 mRNA mediated by YTHDF2, thereby participating in OC immune therapy resistance and optimizing the TIME to inhibit breast cancer progression.